These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 30597600

  • 1. Peripherally acting μ-opioid antagonist for the treatment of opioid-induced constipation: Systematic review and meta-analysis.
    Nishie K, Yamamoto S, Yamaga T, Horigome N, Hanaoka M.
    J Gastroenterol Hepatol; 2019 May; 34(5):818-829. PubMed ID: 30597600
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.
    Nee J, Zakari M, Sugarman MA, Whelan J, Hirsch W, Sultan S, Ballou S, Iturrino J, Lembo A.
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1569-1584.e2. PubMed ID: 29374616
    [Abstract] [Full Text] [Related]

  • 3. Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation.
    Vijayvargiya P, Camilleri M, Vijayvargiya P, Erwin P, Murad MH.
    Aliment Pharmacol Ther; 2020 Jul; 52(1):37-53. PubMed ID: 32462777
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis.
    Ouyang R, Li Z, Huang S, Liu J, Huang J.
    Pain Med; 2020 Nov 01; 21(11):3224-3232. PubMed ID: 32488259
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis.
    Kistemaker KRJ, Sijani F, Brinkman DJ, de Graeff A, Burchell GL, Steegers MAH, van Zuylen L.
    Cancer Treat Rev; 2024 Apr 01; 125():102704. PubMed ID: 38452708
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis.
    Ford AC, Brenner DM, Schoenfeld PS.
    Am J Gastroenterol; 2013 Oct 01; 108(10):1566-74; quiz 1575. PubMed ID: 23752879
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.
    White WB, Kowey P, Diva U, Sostek M, Tummala R.
    J Cardiovasc Pharmacol Ther; 2018 Jul 01; 23(4):309-317. PubMed ID: 29504415
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review.
    Mehta N, O'Connell K, Giambrone GP, Baqai A, Diwan S.
    Postgrad Med; 2016 Jul 01; 128(3):282-9. PubMed ID: 26839023
    [Abstract] [Full Text] [Related]

  • 9. Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients.
    van Malderen K, Halawi H, Camilleri M.
    Neurogastroenterol Motil; 2018 May 01; 30(5):e13250. PubMed ID: 29119706
    [Abstract] [Full Text] [Related]

  • 10. Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.
    Streicher JM, Bilsky EJ.
    J Pharm Pract; 2018 Dec 01; 31(6):658-669. PubMed ID: 28946783
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
    Esmadi M, Ahmad D, Hewlett A.
    J Gastrointestin Liver Dis; 2019 Mar 01; 28(1):41-46. PubMed ID: 30851171
    [Abstract] [Full Text] [Related]

  • 12. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
    Song X, Wang D, Qu X, Dong N, Teng S.
    Expert Rev Clin Pharmacol; 2019 Feb 01; 12(2):121-128. PubMed ID: 30652502
    [Abstract] [Full Text] [Related]

  • 13. Investigational opioid antagonists for treating opioid-induced bowel dysfunction.
    Mozaffari S, Nikfar S, Abdollahi M.
    Expert Opin Investig Drugs; 2018 Mar 01; 27(3):235-242. PubMed ID: 29266973
    [Abstract] [Full Text] [Related]

  • 14. Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs.
    Li Z, Pergolizzi JV, Huttner RP, Zampogna G, Breve F, Raffa RB.
    J Clin Pharm Ther; 2015 Dec 01; 40(6):615-9. PubMed ID: 26573866
    [Abstract] [Full Text] [Related]

  • 15. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
    Corsetti M, Tack J.
    Drugs Today (Barc); 2015 Aug 01; 51(8):479-89. PubMed ID: 26380386
    [Abstract] [Full Text] [Related]

  • 16. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
    Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC.
    Lancet Gastroenterol Hepatol; 2017 Aug 01; 2(8):555-564. PubMed ID: 28576452
    [Abstract] [Full Text] [Related]

  • 17. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
    Holder RM, Rhee D.
    Pharmacotherapy; 2016 Mar 01; 36(3):287-99. PubMed ID: 26945548
    [Abstract] [Full Text] [Related]

  • 18. Naloxegol: a review of its use in patients with opioid-induced constipation.
    Garnock-Jones KP.
    Drugs; 2015 Mar 01; 75(4):419-25. PubMed ID: 25666542
    [Abstract] [Full Text] [Related]

  • 19. Improving the recognition and diagnosis of opioid-induced constipation in clinical practice.
    Gupta A.
    J Fam Pract; 2015 Oct 01; 64(10 Suppl 1):. PubMed ID: 26561554
    [Abstract] [Full Text] [Related]

  • 20. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.
    Jones R, Prommer E, Backstedt D.
    Am J Hosp Palliat Care; 2016 Nov 01; 33(9):875-880. PubMed ID: 26150678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.